Select Page

David R. Liu, PhD
Plenary Speaker
Precision Genome Editing and Progeria
Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, Director of the Chemical Biology and Therapeutic Sciences Program, Core Institute Member and Vice-Chair of the Faculty, Broad Institute. Investigator, Howard Hughes Medical Institute, Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry & Chemical Biology, Harvard University – Boston, MA

Leslie Gordon, MD, PhD
Plasma progerin changes with lonafarnib therapy -association with drug effect and extended survival
Medical Director and Chair, Organizing Committee,The Progeria Research Foundation, Brown University, Hasbro Children’s Hospital, Boston Children’s Hospital, and Harvard Medical School- Boston, MA

Vicente Andrés, PhD
Novel molecular and cellular mechanisms underlying HGPS
Professor, Laboratory of Molecular and Genetic Cardiovascular Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)- Madrid, Spain

Abigail Buchwalter, PhD
Combined proteome-wide measurements of protein and cell turnover across tissues accounts for the tissue specificity of progeria
Assistant Professor, Cardiovascular Research Institute and the Department of Physiology at the University of California- San Francisco, CA

Francis Collins, MD, PhD
Racing for progeria cures with RNA and DNA therapies
Director, National Institutes of Health, Bethesda, MD

Mario Cordero, PhD
Lessons from the inflammasomes in the pathophysiology of Progeria
Researcher, Biomedical Research and Innovation Institute of Cadiz (INIBICA)- Cadiz, Spain

Karima Djabali, PhD
Modulation of JAK-STAT Signaling in Hutchinson-Gilford progeria syndrome
Epigenetics of Aging, Department of Dermatology and Allergy, TUM school of Medicine, Technical University of Munich (TUM), Germany.

Maria Eriksson, PhD
Transient base editor expression corrects the progeria mutation in mice
Professor, Karolinska Institutet- Huddinge, Sweden

Roland Foisner, PhD
Endothelial and systemic upregulation of miR-34a-5p fine-tunes senescence in progeria
Professor, Medical University Vienna, Max Perutz Labs – Vienna, Austria

Jay Humphrey, PhD
Evolving vascular phenotypes and cardiovascular consequences in a mouse model of HGPS and its treatment
Professor, Department of Biomedical Engineering Yale University- New Haven, CT

Monica Kleinman, MD
Everolimus plus lonafarnib clinical trial outcomes
Clinical Director, Medical/Surgical Intensive Care Unit; Medical Director, Transport Program; Senior Associate in Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital and Harvard Medical School – Boston, MA

Chiara Lanzulo, PhD
Genome function’s recovery upon pharmacological treatments in Hutchinson Gilford Progeria Syndrome
Senior researcher, Institute of Biomedical Technologies (ITB)-CNR, Chromatin and Nuclear architecture Laboratory at Istituto Nazionale di Genetica Molecolare – Milan, Italy

Giovanna Lattanzi, PhD
Adipocyte-specific effects of drug treatments in HGPS
Research Director, CNR Institute of Molecular Genetics- Bologna, Italy

 

Elsa Logarinho, PhD
Small-molecule correction of microtubule-dependent genotoxic stress in HGPS cells bypasses progerin-driven cellular phenotypes

Researcher, Instituto de Biologia Molecular e Celular (IBMC) Instituto de Inovação e Investigação em Saúde- Porto, Portugal

Tom Misteli, PhD
New cellular pathways and therapeutic approaches in HGPS
Director, National Cancer Institute, National Institutes of Health- Bethesda, MD

Ashwin Prakash, MD
Update on echocardiographic abnormalities in HGPS: follow up data and new deformation measures
Associate Professor of Pediatrics, Boston Children’s Hospital, Harvard Medical School- Boston, MA